From what 0 stock analysts predict, the share price for NeuroOne Medical Technologies Corporation (NMTC) might decrease by 100% in the next year. This is based on a 12-month average estimation for NMTC. Price targets go from $ to $. The majority of stock analysts believe NMTC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedNMTC 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect NeuroOne Medical Technologies Corporation to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NMTC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of NMTC.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Ben Haynor Alliance Global Partners | Buy | $2.2 | Maintains | Aug 15, 2023 |
Alexander Nowak Craig-Hallum | Hold | Downgrade | Mar 28, 2022 | |
Alliance Global Partners | Buy | Initiates | Dec 3, 2021 | |
Craig-Hallum | Buy | Initiates | Nov 15, 2021 |
When did it IPO
N/A
Staff Count
16
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. David A. Rosa M.D.
Market Cap
$28.7M
In 2023, NMTC generated $2.0M in revenue, which was a increase of 1,040.65% from the previous year. This can be seen as a signal that NMTC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.